Finding a cure: how big pharma can tackle counterfeiting
Counterfeit medications are one of the most worrisome issues for the pharmaceutical industry. The complexities of the global marketplace, from elaborate international supply chains to digital transactions that increasingly take place online and are consequently more difficult to monitor, have combined to make the task of identifying, tracking and policing the production and sale of counterfeit drugs more formidable than ever.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
24 December 2025 John Squires has rewired the country’s patents system since becoming USPTO director—but which changes are most impactful? Sarah Speight explores.
22 December 2025 Biopharma company and two others have taken action against numerous defendants over proposed generic versions of Livmarli, Mirum’s core revenue driver.